Ajovy, a CGRP inhibitor prescribed for migraine prevention, may cause hair loss in rare cases. Clinical trials reported alopecia in less than 1% of patients.
Ajovy targets calcitonin gene-related peptide (CGRP), a molecule involved in migraine pain pathways. By blocking CGRP, it reduces migraine frequency and severity. This mechanism differs from traditional migraine preventatives like beta-blockers or anticonvulsants.
The FDA-approved label lists alopecia as a potential side effect, though it occurs infrequently. A 2018 study in JAMA Neurology noted hair thinning in 0.6% of patients taking CGRP inhibitors. Most cases were mild and reversible upon discontinuation.
One patient reported to the FDA Adverse Event Reporting System experienced noticeable hair shedding after six months of Ajovy injections. Hair regrowth occurred three months after stopping treatment.
Researchers hypothesize CGRP inhibitors might disrupt hair follicle cycles by altering blood flow or cellular signaling in the scalp. However, the exact relationship between CGRP and hair growth remains unclear.
For context, hair loss can result from various factors beyond medication. Conditions like telogen effluvium (stress-related shedding) or androgenetic alopecia (pattern baldness) may coincide with Ajovy use but aren't necessarily caused by it.
Unlike chemotherapy-induced alopecia, which causes complete hair loss within weeks, Ajovy-related hair loss typically presents as gradual thinning over months. The pattern often resembles telogen effluvium rather than male or female pattern baldness.
As someone who's managed chronic migraines for years, I understand the importance of weighing treatment benefits against potential side effects. While hair loss from Ajovy is uncommon, being informed allows for better shared decision-making with healthcare providers.